| First Author | Andricovich J | Year | 2018 |
| Journal | Cancer Cell | Volume | 33 |
| Issue | 3 | Pages | 512-526.e8 |
| PubMed ID | 29533787 | Mgi Jnum | J:258620 |
| Mgi Id | MGI:6144241 | Doi | 10.1016/j.ccell.2018.02.003 |
| Citation | Andricovich J, et al. (2018) Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors. Cancer Cell 33(3):512-526.e8 |
| abstractText | KDM6A, an X chromosome-encoded histone demethylase and member of the COMPASS-like complex, is frequently mutated in a broad spectrum of malignancies and contributes to oncogenesis with poorly characterized mechanisms. We found that KDM6A loss induced squamous-like, metastatic pancreatic cancer selectively in females through deregulation of the COMPASS-like complex and aberrant activation of super-enhancers regulating DeltaNp63, MYC, and RUNX3 oncogenes. This subtype of tumor developed in males had concomitant loss of UTY and KDM6A, suggesting overlapping roles, and points to largely demethylase independent tumor suppressor functions. We also demonstrate that KDM6A-deficient pancreatic cancer is selectively sensitive to BET inhibitors, which reversed squamous differentiation and restrained tumor growth in vivo, highlighting a therapeutic niche for patient tailored therapies. |
